Literature DB >> 8168558

Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.

F W Goldstein1, P Geslin, J F Acar.   

Abstract

The MICs of teicoplanin and vancomycin were determined for 400 penicillin-susceptible and -resistant strains of Streptococcus pneumoniae isolated during a multicenter study in 1992. Teicoplanin displayed a four-fold better activity than vancomycin, with modal MICs of these agents being 0.06 and 0.25 micrograms/ml, respectively. These data warrant further studies with teicoplanin in the treatment of pneumococcal infections.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8168558     DOI： 10.1007/bf02026121

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  13 in total

1.  Comparative in-vitro activity of four peptide antibiotics against penicillin-resistant Streptococcus pneumoniae isolated from cerebrospinal fluid (CSF).

Authors:  J L Rodríguez-Tudela; F López de Felipe; J V Martínez-Suárez; A Fenoll
Journal:  J Antimicrob Chemother       Date:  1992-03       Impact factor: 5.790

Review 2.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  [Pneumococci are resistant to antibiotics, too].

Authors:  F Peyreffitte; A Galland; C Malhuret; F W Goldstein; A Bouvet
Journal:  Nouv Presse Med       Date:  1979-03-10

4.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  The bactericidal activity of vancomycin and teicoplanin against Streptococcus pneumoniae.

Authors:  D Felmingham; P Foxall; M O'Hare; R Grüneberg
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 8.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

9.  Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.

Authors:  P C Appelbaum; S K Spangler; E Crotty; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

10.  A seventeen-year epidemiological survey of antimicrobial resistance in pneumococci in two hospitals.

Authors:  A Y Buu-Hoï; F W Goldstein; J F Acar
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790
View more
  8 in total

1.  Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.

Authors:  E Fasola; S K Spangler; L M Ednie; M R Jacobs; S Bajaksouzian; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

2.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 5.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

6.  Capsular types and antimicrobial resistance of Streptococcus pneumoniae isolated in Korea.

Authors:  Y Chong; K Lee; O H Kwon; J Henrichsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

7.  Activity of teicoplanin and vancomycin against penicillin-resistant pneumococci.

Authors:  K P Klugman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

8.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.